Nerandomilast (2) – Jascayd®
Idiopathic pulmonary fibrosis
Characteristics
| Start date | 15.08.2026 |
|---|---|
| Resolution | 04.02.2027 – active procedure |
| INN | Nerandomilast |
| Brand name | Jascayd® |
| Pharm. company | Boehringer Ingelheim Pharma GmbH und Co. KG |
| G-BA Procedure ID | D-1364 |
| Therapeutic area | Respiratory system diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions